BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization.
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, Europe, and Japan, the company expects to report results from registrational trials of infigratinib, encaleret, and BBP-418, and it could have as many as four products on the market by the end of 2026.
BridgeBio’s (BBIO) FDA Approval Sparks Surge in Stock Price—What’s Next?
(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by the U.
BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
Stocktwits on MSN2d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds
BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
ETF Daily News16h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
Business Insider11h
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...
BridgeBio price target raised to $45 from $42 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
bovnews3d
Why Did BridgeBio Pharma Inc (BBIO) Stock Plunge -1.26% Last Week?
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.
Why Was A.P. Bio Canceled Twice? Everything to Know About the Sitcom's History (And How Fans Brought It Back!) Before It Landed on Netflix
A.P. Bio' starring Glenn Howerton aired for two seasons on NBC and two seasons on Peacock. Here's everything to know about ...